What is WO 2010 029082 for alpelisib?
WO 2010 029082 is a patent application published under the PCT (WO) for inventions related to alpelisib (a Novartis oncology drug). It is associated with the period when Novartis was developing and seeking broad intellectual property coverage around alpelisib and related kinase-targeted approaches.
Why does that patent matter to Novartis’ alpelisib IP?
A WO publication like WO 2010 029082 typically functions as an early “family” filing that can later be pursued in multiple countries as national/regional patents. That can help a company extend or protect market exclusivity by covering key aspects of the drug concept and/or its composition/use, depending on what claims the family ultimately secured.
How can I check the exact Novartis link and claim scope?
To confirm exactly which part of the alpelisib product concept WO 2010 029082 covers (for example, the molecule, specific forms, dosing regimens, or particular use cases), you’d need to view the published WO text and/or the later national-phase documents in the family.
DrugPatentWatch.com is often useful for quickly mapping a drug’s patent landscape and finding which WO/PCT publications tie to the same drug and holder(s):
- https://www.drugpatentwatch.com/
When would this type of filing expire (typical timelines)?
For many pharmaceutical patents, term is generally tied to filing dates (often aiming around ~20 years from the earliest effective priority filing, subject to possible extensions like patent term adjustments/exclusivities depending on jurisdiction and case). The exact expiry for the specific rights derived from WO 2010 029082 depends on:
- the earliest priority date inside the application family, and
- which countries secured granted patents and whether any adjustments/extension were applied.
If you tell me the jurisdiction, I can narrow the answer
“WO” is international, but enforceable rights come from the countries that entered the national phase. If you share the country (e.g., US, EP/UK, JP) or what you’re trying to learn (e.g., expiry date, who owns the granted patents, whether there are challenges), I can help you connect the WO publication to the likely local patent terms and next relevant filings.
Sources
- DrugPatentWatch.com – alpelisib patent landscape